Clinical outcomes after early ambulatory multidrug therapy for high-risk SARS-CoV-2 (COVID-19) infectionArticle Published on 2020-12-302023-07-13 Journal: Rev Cardiovasc Med [Category] SARS, [키워드] ambulatory Antiviral Azithromycin Corticosteroid COVID-19 doxycycline Hospitalization Hydroxychloroquine Ivermectin Mortality multidrug SARS-CoV-2 Vitamin Zinc [DOI] 10.31083/j.rcm.2020.04.260
Comparative efficacy and safety of pharmacological interventions for the treatment of COVID-19: A systematic review and network meta-analysisCOVID-19 치료를 위한 약리학적 중재의 비교 효능 및 안전성: 체계적인 검토 및 네트워크 메타 분석Meta-Analysis Published on 2020-12-302022-08-13 Journal: PLoS Medicine [Category] Biology and Life Sciences, MERS, meta-analysis, 임상, [키워드] 1.26 95% CI 95% confidence interval Admission aggravation Alpha Anakinra analyses Analysis anti-inflammatory agent anti-inflammatory agents Asia assessment associations Azithromycin benefit Cardiac complications cardiac safety risk cardiac safety risks cardiac-impaired population cardiac-impaired populations carried categories category Causality certainty clinical clinical benefit clinical benefits Clinical outcome clinical settings clinical trial ClinicalTrials clinician Cochrane Library collected Combination Comparative controlled trials convalescent plasma coronavirus disease Coronavirus disease 2019 Corticosteroid Corticosteroids Course COVID-19 COVID-19 disease COVID-19 disease course COVID-19 treatments CRD42020186527 Critically ill Critically ill patient critically ill patients daclatasvir dataset determine development disease course drug effective Efficacy and safety eligibility criteria eligible Europe evaluate Evidence evidence of fatal cardiac complication fatal cardiac complications Google Scholar help heterogeneous High-dose Hospitalization hospitalized COVID-19 patients Hydroxychloroquine ICU Immunoglobulin information intensive care intensive care unit interferon interferon-alpha Intravenous immunoglobulin investigated itolizumab Ivermectin IVIG Level management mechanical ventilation medRxiv Meta-analysis Middle East mild patients moderate moderate to severe moderate/high evidence certainty Mortality mortality rate mortality rates Network meta-analysis NMA non-ICU non-ICU setting noncardiac serious adverse events North America Numerous observational studies observational study Odds ratio outcome Patient patients hospitalized pharmacological agent pharmacological intervention pharmacological interventions pharmacological management plasma Policy populations Potential treatment potential treatments progression PROSPERO provide QT prolongation QT prolongation incidence Randomized controlled trial Randomized controlled trials randomized trial randomized trials RCT RCTs recommendations reduce reduce COVID-19 aggravation reduce mortality rate reduced reflected registry Remdesivir Research researcher Result risk risk of bia RoB RoB2 ROBINS-I framework searched self-limiting disease Serious Adverse Event Serious Adverse Events severe COVID-19 patient severe disease severe pneumonia shown significantly sofosbuvir sofosbuvir plus daclatasvir South America SSRN standard care Study protocol supported systematic review systematic synthesis Tocilizumab translated Treatment treatment regimen viral clearance rate vulnerable population WHO WHO International Clinical Trials Registry Platform [DOI] 10.1371/journal.pmed.1003501 PMC 바로가기 [Article Type] Meta-Analysis
Known drugs and small molecules in the battle for COVID-19 treatmentReview article Published on 2020-12-012022-10-05 Journal: Genes & Diseases [Category] 치료법, 치료제, [키워드] Chloroquine clinical trial Combination components controlled trials coronavirus COVID-19 death drug drugs enzyme Famotidine FIVE hospital human cells Ivermectin knowledge lack Nicotine occurred other diseases outbreak pandemic Placebo Randomized Remdesivir replicate Replication SARS-CoV2 small molecule Transport treat Treatment virus while World Health Organization zinc ion [DOI] 10.1016/j.gendis.2020.06.007 [Article Type] Review article
Considerations on the article «antiviral and anti-inflammatory properties of ivermectin and its potential use in COVID-19»Correspondence Published on 2020-12-012022-10-05 Journal: Archivos de bronconeumología [Category] 치료제, [키워드] anti-inflammatory property Ivermectin [DOI] 10.1016/j.arbr.2020.08.010 [Article Type] Correspondence
Antiviral and anti-inflammatory properties of ivermectin and its potential use in Covid-19Correspondence Published on 2020-12-012022-10-05 Journal: Archivos de bronconeumología [Category] 치료제, [키워드] anti-inflammatory property Ivermectin [DOI] 10.1016/j.arbr.2020.06.006 [Article Type] Correspondence
Development of a Minimal Physiologically-Based Pharmacokinetic Model to Simulate Lung Exposure in Humans Following Oral Administration of Ivermectin for COVID-19 Drug RepurposingShort communication Published on 2020-12-012022-10-05 Journal: Journal of pharmaceutical sciences [Category] SARS, 신약개발, 치료제, [키워드] ACE2 receptor Antiviral antiviral activity cellular Combination Concentration COVID-19 described determine develop development doses drug Efficacy exposure geometric host cell Human human lung humans IC50 Importins in vitro Inhaled inhibiting Ivermectin Kinetics less lung lung tissue mechanism Minimal physiologically-based pharmacokinetic model Model nuclei oral pharmacokinetic Pharmacokinetic/pharmacodynamic (PK/PD) modeling pharmacokinetics Pharmacometrics Physiologically based pharmacokinetic modeling plasma plasma concentration profile reached reported repurposing SARS-CoV-2 shown subunit therapeutic potential were used [DOI] 10.1016/j.xphs.2020.08.024 [Article Type] Short communication
Ivermectin to prevent hospitalizations in patients with COVID-19 (IVERCOR-COVID19): a structured summary of a study protocol for a randomized controlled trialCOVID-19(IVERCOR-COVID19) 환자의 입원을 방지하기 위한 Ivermectin: 무작위 대조 시험을 위한 연구 프로토콜의 구조화된 요약Randomized Controlled Trial Published on 2020-11-242022-08-13 Journal: Trials [Category] SARS, 임상, 치료기술, [키워드] 1:1 acute infectious disease addition adherence administration Admission adverse event adverse events age allergy analyzed Anthropometric data antiviral drug antiviral drugs Arm ARMS assessment barrier basal blinded Breastfeeding breastfeeding women Cardiology Care care providers carried cause Chain Reaction childbearing age Chloroquine cirrhosis component components Concomitant Concomitant medication Confirmed connection contraceptive method contraceptives Control control group control groups coordination Corriente COVID-19 COVID-19 patient population criteria current Day death demographic demographic data Diagnosis diagnosis of COVID-19 dialysis discharged dissemination dose double-blind drug Efficacy Efficacy and safety elapsed element EOS Equal example exclusion criteria Final final visit first dose Follow-up greater heart rate Hospitalization hospitalizations Hydroxychloroquine incidence include Inclusion inclusion criteria inclusion/exclusion criteria Informed consent Intervention Invasive mechanical ventilation investigator investigators Ivermectin Ivermectin safety Laboratory less liver Liver cirrhosis Liver disease mal-absorptive syndrome medical history medication menstrual menstrual cycles Mortality negative Negative PCR number objective outcome outcome assessor outcome assessors over oxygen oxygen saturation parallel group participant Participants Participation Patient patients with COVID-19 PCR PCR swab Placebo placebo-controlled study polymerase chain polymerase chain reaction Polymerase chain reaction test postmenopausal pregnant Presence Prevent Primary outcome protocol Public public health randomization Randomized Randomized controlled trial randomly permuted blocks receive recommendation recorded recruitment reducing renal replacement therapy replacement therapy reproductive required Research Sample size SARS-CoV2 secondary severe liver disease single-center standard treatment standard treatment alone Study protocol supplementary material surgical Swab table Tablet temperature the patient Total Treatment Trial Trial registration use of hydroxychloroquine Version Viral viral pathology Vital vital signs vital status web system website weight woman women [DOI] 10.1186/s13063-020-04813-1 PMC 바로가기 [Article Type] Randomized Controlled Trial
Lack of efficacy of standard doses of ivermectin in severe COVID-19 patientsResearch Article Published on 2020-11-112022-10-28 Journal: PLoS ONE [Category] COVID-19, MERS, SARS, [키워드] Efficacy groups High-dose In-vitro Ivermectin outcome Patient randomized trial receiving SARS-CoV-2 severe COVID-19 patient shown Standard dose [DOI] 10.1371/journal.pone.0242184 PMC 바로가기 [Article Type] Research Article
Toward Preparing a Knowledge Base to Explore Potential Drugs and Biomedical Entities Related to COVID-19: Automated Computational ApproachOriginal Paper Published on 2020-11-102022-10-31 Journal: JMIR Medical Informatics [Category] COVID-19, [키워드] 2019-nCoV Analysis applicability applied approach association automated base clinical status Community computational method confidence score coronavirus coronavirus disease COVID-19 deep learning Dexamethasone disease Diseases drug drug side effects drugs effective effective drug Effectiveness effort entity Evidence Genes help highlight human genes human miRNAs Hydroxychloroquine IMPROVE information Interaction Ivermectin labeling lower mortality novel objective patients hospitalized pharmacological treatment platform Potential Preparing public health Remdesivir Research resources Result resulting SARS SARS-CoV-2 Scientific community similarity statin statins Therapeutic treatment Treatment Vaccine with COVID-19 [DOI] 10.2196/21648 PMC 바로가기 [Article Type] Original Paper
What to expect from different drugs used in the treatment of COVID-19: A study on applications and in vivo and in vitro resultsResearch article Published on 2020-11-012022-10-05 Journal: European journal of pharmacology [Category] 치료법, 치료제, [키워드] Anticoagulants antivirals carried Chloroquine clinical study coronavirus COVID-19 Dexamethasone drug effective help in vitro result in vivo Ivermectin knowledge performed SARS-CoV-2 Spread suggested Treatment treatments for COVID-19 [DOI] 10.1016/j.ejphar.2020.173467 [Article Type] Research article